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DynamicsTwo analyses of HIV-1 subtype C Gag quasispecies were performed in a prospective cohort of 42 acutely and
recently infected individuals by SGA on viral RNA/proviral DNA templates. First, in vivo Gag substitutions
were assessed in relation to the HIV-1C consensus sequence, which revealed that 29.3% of detected amino
acid substitutions can be classiﬁed as reversions to subtype consensus, 61.3% as forward substitutions from
subtype consensus, and 9.3% as polymorphisms not associated with the subtype consensus sequence. Second,
the proportion, dynamics, and relationships within individual pools of viral quasispecies were analyzed.
Among reverse substitutions, 16.1% were minor, 11.0% transient, 13.6% dominant, and 59.2% ﬁxed. In con-
trast, 31.6% of forward substitutions were minor, 59.3% transient, 3.8% dominant, and 5.3% ﬁxed. The distinct
patterns in the spectrum and dynamics of reverse and forward Gag substitutions suggest that these differ-
ences should be considered in HIV-1 evolutionary studies and analyses of viral mutational pathways.ealth AIDS Initiative, FXB 402,
.
).
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
A comprehensive assessment of viral evolution across HIV-1 genes
is critical for the successful design of preventive and therapeutic in-
terventions. Host-driven immune pressure involving both innate
and adaptive components during the course of HIV infection results
in a robust quasi-steady balance between emerging viral variants
and virus ﬁtness (Borghans et al., 2007; Crawford et al., 2007; Leslie
et al., 2004; Liu et al., 2007; Martinez-Picado et al., 2006; Peyerl et
al., 2004b). The ﬁrst virus-mediated T cell response can rapidly select
escape mutations concurrent with the peak decline in acute HIV in-
fection (Goonetilleke et al., 2009). Successful viral escape from im-
mune recognition can maintain viral replication (Feeney et al.,
2004; Geels et al., 2006; Oxenius et al., 2004). However, if the escape
mutation impairs virus replicative ﬁtness, such escape might be asso-
ciated with reduced viral load and better disease outcome in humans
and rhesus macaques (Chopera et al., 2008; Crawford et al., 2007;
Friedrich et al., 2004a,b,c; Goepfert et al., 2008; Martinez-Picado et
al., 2006; Migueles et al., 2003; Peyerl et al., 2004a,b; Schneidewind
et al., 2007). For example, in subjects expressing HLA-B*57/5801,
the virus mutates from Thr to Asn at position 242 in Gag which results
in a reduction of viral replication due to the ﬁtness cost of the T242N
mutation (Brockman et al., 2007; Chopera et al., 2008; Crawford et al.,2007; Leslie et al., 2004; Martinez-Picado et al., 2006). Because host
genetic factors play an important role in disease progression in HIV-
infected individuals (Carrington et al., 1999; Fellay et al., 2007;
Kaslow et al., 1996; Klein et al., 1998; O'Brien and Nelson, 2004), it
is believed that the pathway of viral escape from immune recognition
can be predicted by the proﬁle of host MHC class I HLA alleles (Allen
et al., 2005; Brumme et al., 2007, 2008a,b; Rousseau et al., 2008).
Transmission of the viral escape variant to a newhostmay result in a
rapid reversion to the wild type virus (which corresponds to the HIV-1
subtype consensus sequence in most epidemics), particularly in the ab-
sence of selective pressure in the new host due to a different proﬁle of
HLA alleles (Allen et al., 2004; Chopera et al., 2008; Crawford et al.,
2007; Davenport et al., 2008; Duda et al., 2009; Friedrich et al., 2004a;
Leslie et al., 2004; Li et al., 2007; Matthews et al., 2008; Rousseau et
al., 2008). Reverse amino acid substitutions to the HIV-1 subtype con-
sensus are critical formaintaining viruswithin the optimal evolutionary
space in the local epidemic. The breadth of immune response plays an
important role in disease outcome, and is likely to be associated with
the breadth of viral mutational pathways. It is widely agreed that viral
escape (or forward) and reverse amino acid substitutions contribute
signiﬁcantly to HIV-1 evolution at both the intra-patient and population
levels (Allen et al., 2005; Bhattacharya et al., 2007; Borrow et al., 1997;
Brumme et al., 2008a; Friedrich et al., 2004a; Koenig et al., 1995; Leslie
et al., 2004, 2005; Li et al., 2007; Moore et al., 2002; Phillips et al., 1991;
Price et al., 1997; Rousseau et al., 2008).While intrapatient evolution of
HIV does not necessarily translate into evolution of HIV at the popula-
tion level (Leslie et al., 2004), it is likely that the circulating variants of
120 V. Novitsky et al. / Virology 421 (2011) 119–128HIV-1 in the local epidemic represent equilibrium between cumulative
immune pressure of the host population and viral ﬁtness of locally
transmitting viruses.
The HIV-1Gag is able to induce potent virus-speciﬁc T cell responses
thatwere shown to be associatedwith control of viral replication, lower
viral set point, and better disease prognosis (Betts et al., 2001; Boaz et
al., 2002; Edwards et al., 2002; Geldmacher et al., 2007; Kiepiela et al.,
2007; Masemola et al., 2004; Ndongala et al., 2009; Novitsky et al.,
2003, 2006; Ramduth et al., 2005; Rolland et al., 2008; Serwanga et al.,
2009; Zuniga et al., 2006), and therefore represents an attractive target
for anHIV-1 vaccine design. Better understanding of viral dynamics and
the spectrum of in vivo Gag substitutions may advance the rational de-
sign and development of an HIV-1 vaccine.
Surprisingly, types of viral amino acid substitutions have not been
deﬁned and used uniformly. While some types of substitutions are
well deﬁned (e.g., synonymous, nonsynonymous, ﬁxed), terms for
other viral substitutions are used inconsistently, leading to confusion
or misunderstanding. For example, “reverse mutation” or “reverse sub-
stitution”maymean reversion either to the transmitted virus, or to sub-
type consensus. Using a detailed classiﬁcation of terms, this study
addressed and characterized the types and frequency of the in vivo
Gag substitutions in the early stage of HIV-1 subtype C infection in a co-
hort of 42 subjects with estimated time of seroconversion. The frequen-
cy distributions of amino acid substitutions within the individual pools
of viral quasispecies were analyzed longitudinally. Two temporal as-
pects in the evolution of in vivo Gag quasispecies were addressed.
Amino acid substitutions across Gag were analyzed by their relation to
the HIV-1 subtype C consensus, and by ﬁxation and stability.
Results
Intra-patient heterogeneity of HIV-1C Gag substitutions
Dynamics of Gag amino acid substitutions was analyzed in a co-
hort of 42 HIV-1 subtype C infected individuals with estimated time
of seroconversion, which allowed us to synchronize the time of ob-
served substitutions among patients. The actual distribution of HIV-
1subtype C Gag substitutions is presented in Supplementary Table
S1. In the cumulative analysis of all types of Gag substitutions, the
median (IQR) number of reverse substitutions was 7 (4–15.5), for-
ward substitutions was 18 (15.3–25), and polymorphisms was 2
(1–4) per subject. The number of Gag substitutions per subject was
considerably less for a subset of dominant and ﬁxed substitutions:
median (IQR) number of reverse amino acid substitutions was 5 (1.3–
8.8); forward substitutions was 1 (0–3), and polymorphisms was
0 (0–1). The reverse dominant and ﬁxed amino acid substitutions in
HIV-1C Gag were found in 37 of 42 (88%) subjects, while forward dom-
inant and ﬁxed substitutions were detected in 27 of 42 (64%) subjects.
To address distribution of amino acid substitutions in HIV-1 sub-
type C Gag, the identiﬁed non-synonymous substitutions were plot-
ted according to their location across Gag in each subject. The
substitution map presented in Fig. 1 shows distribution of three
types of Gag substitutions – reverse (green up-triangles), forward
(red down-triangles), and polymorphisms not associated with the
subtype consensus sequence (gray circles) – that were accumulated
over the follow-up period (up to 500 days p/s). The map in Fig. 1 in-
cludes all minor, transient, dominant, and ﬁxed substitutions in
HIV-1C Gag. It is evident from this map that 1) all types of substitu-
tions are scattered across Gag; 2) the number and type of Gag substi-
tutions differ substantially between subjects, and 3) forward (red)
substitutions dominate the map (Fig. 1). However, excluding of
minor and transient substitutions revealed in a changed shape of
the Gag substitution map (Fig. 2). The reverse substitutions (green)
are prevailing on the map of dominant and ﬁxed Gag substitutions,
while forward substitutions are less common. The location and num-
ber of dominant and ﬁxed substitutions differ considerably betweensubjects. Substitutions at Gag codon position 242 represented the
most common pattern observed in 12 out of 42 subjects including 5
reverse, 5 forward, and 2 polymorphic substitutions, as described
elsewhere (Novitsky et al., 2010c).
Overall, the analysis of viral amino acid substitutions by their rela-
tion to the subtype consensus sequence demonstrated the wide range
and heterogeneity in the number and location of reverse and forward
Gag substitutions among HIV-1 subtype C infected individuals.
Differential dynamics of Gag substitutions
Temporal trends in kinetics of reverse and forward Gag substitu-
tions in primary HIV-1 subtype C were analyzed over ﬁve 100-day in-
tervals up to 500 days p/s (Fig. 3). Forward Gag substitutions were
predominant among minor (Fig. 3A) and transient (Fig. 3B) substitu-
tions, except even distribution of minor reverse and minor forward
substitutions during the period 0 to 100 days p/s. The relationships
between reverse and forward transient substitutions in Gag were re-
markably constant over time (Fig. 3B). In contrast, the reverse substi-
tutions outnumbered forward substitutions among dominant
(Fig. 3C) and ﬁxed (Fig. 3D) Gag substitutions during the period up
to 300 days p/s. However a larger proportion of forward substitutions
was evident during 301–400 days p/s with about equal number
of forward and reverse dominant and ﬁxed substitutions over the pe-
riod 401–500 days p/s. This observation suggests a shift in the ratio of
reverse/forward amino acid substitution in HIV-1 subtype C Gag
around 300 days p/s. The Fisher exact test supported that the fre-
quencies of reverse substitutions within total substitutions were
changing over time (p-value for minor, transient, dominant, and
ﬁxed substitutions was equal to 0.001, 0.36, b0.001, and b0.001, re-
spectively). The observed shift in the ratio of reverse/forward substi-
tutions after 300 days p/s seems to indicate fewer reversions that
occur after the ﬁrst year of HIV-1 infection.
Changes in the spectrum of reverse and forward Gag substitutions
were analyzed over ﬁve 100-day intervals (Fig. 4). A gradual shift over
time was evident in the range of both reverse (Fig. 4A) and forward
(Fig. 4B) substitutions. Among reverse Gag substitutions, gradual de-
crease of dominant and ﬁxed substitutions was accompanied by in-
creased proportion of minor and transient substitutions, which was
particularly noticeable after 300 days p/s. Interestingly that among
Gag forward substitutions, the fraction of complete substitutions was
substantial (10 of 28) at the early stage of HIV-1 subtype C infection
(Fig. 4B). However, the proportion of dominant and ﬁxed amino acid
substitutions among Gag forward substitutions diminished dramatical-
ly at later time points, e.g., after 100 days p/s. As a result, themajority of
Gag forward substitutions after 100 days p/s were minor and transient.
The proportion of individuals with detectable reverse or forward
amino acid substitutions in Gag was analyzed over the same ﬁve 100-
day intervals (Fig. 5). A gradual decrease from about 80% to 40% of indi-
viduals with detectable reverse substitutions was evident over time. In
contrast, the proportion of individuals with detectable forward substi-
tutions was the highest during the 201–300 days p/s interval.
Time to ﬁxation of amino acid substitutions in Gag was analyzed
for different types of substitutions. The median (IQR) to ﬁxation
was 146 (100–185) days p/s for reverse substitutions, 268 (102–
380) days p/s for forward substitutions, and 243 (190–440) days p/s
for polymorphisms. The difference between time to ﬁxation was sta-
tistically signiﬁcant between reverse and forward substitutions
(pb0.001), and between reverse substitutions and polymorphisms
(pb0.001), but was similar between forward substitutions and poly-
morphisms not associated with subtype consensus sequence.
Relationships between types of amino acid substitutions in Gag
The quantitative relationships between different types of amino
acid substitutions were analyzed. The proportions of total reverse
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Fig. 1. Proﬁle and location of total amino acid substitutions across Gag in a cohort of 42 HIV-1 subtype C-infected individuals. The cumulative non-synonymous substitutions iden-
tiﬁed by SGA during the time period from seroconversion to up to 500 days p/s are presented. The study subjects' code is shown at the left. Eight acutely infected subjects are
highlighted. Three types of Gag substitutions are outlined as follows: green up triangle shows amino acid substitutions toward the HIV-1 subtype C consensus sequence – reverse
substitutions, red down triangle denotes amino acid substitutions from the subtype C consensus – forward substitutions, and gray circle delineates viral amino acid polymorphisms
not associated with the subtype C consensus sequence. Gray bars on the background denote HIV-1 Gag p17, p24, p2/p7p1/p6 for each subject.
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associated with the subtype consensus in Gag were 30.8%, 59.6%, and
9.7%, respectively (Fig. 6A). The majority of reverse substitutions
reached dominance (13.5%) and ﬁxation (60.2%; Fig. 6B). In contrast,
forward amino acid substitutions were predominantly minor (31.3%)
or transient (58.5%), while only few reached dominance (4.1%) or ﬁx-
ation (6.1%) in the pool of viral quasispecies during the ﬁrst year of
HIV-1 subtype C infection (Fig. 6B). A large fraction of viral polymor-
phisms not associated with the subtype consensus sequence was
represented by minor (21.1%) or transient (55.0%) substitutions,
and only about a quarter of polymorphisms reaching dominance
(15.6%) or ﬁxation (8.3%) within a year following seroconversion
(Fig. 6B). Overall, 68.9% of Gag amino acid substitutions did not ex-
ceed the level of 50% or were lost during the observation period(Fig. 6C). Of those, 36.9% were represented by minor amino acid sub-
stitutions, and 63.1% by transient substitutions. About one third of
Gag substitutions (31.1%) reached dominance or ﬁxation. Among
these substitutions, 26.1% remained dominant, while 73.9% reached
ﬁxation (Fig. 6C).
Amino acid substitutions in Gag within known CTL epitopes
To estimate the fraction of amino acid substitutions that are likely
to be associated with immune pressure we quantiﬁed substitutions
within known CTL epitopes restricted by individual MHC class I HLA
alleles in each subject. A total of 462 of 1243 (37.2%) observed
amino acid substitutions in Gag were observed with known CTL epi-
topes restricted by individual class I HLA alleles. The restriction of
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Fig. 2. Proﬁle and location of dominant and ﬁxed amino acid substitutions across HIV-1C Gag. See legend to Fig. 1. The dashed line highlights 12 amino acid substitutions observed at
Gag codon position 242.
122 V. Novitsky et al. / Virology 421 (2011) 119–128involved epitopes was approximately even between HLA-A (31.2%),
HLA-B (37.4%), and HLA-C (31.4%) loci. The proportion of different
types of amino acid substitutions found within known CTL epitopes
was similar to the overall distribution of substitutions in Gag: 29%,
63%, and 9% for reversions, forward substitutions, and polymor-
phisms, respectively. Interestingly, 48% of reverse substitutions and
39% of forward substitutions were found within known CTL epitopes
restricted by more than one class I HLA allele. For example, a gradual
substitution from Lys to Arg at position 26 in p17 was observed with-
in known overlapping CTL epitope KIRLRPGGK restricted by HLA-
A*03:01 and epitope RPGGKKRYM restricted by HLA-Cw*06:02 in re-
cently infected subject OG-2604 expressing both HLA-A*03:01:01
and HLA-Cw*06:02. The median (IQR) of observed Gag substitutions
within known CTL epitopes per patient was 9 (6; 14) ranging from
1 to 46.Discussion
The study assessed the dynamic spectrum and inter-subject hetero-
geneity of the in vivo Gag substitutions during primary HIV-1 subtype
C infection. Longitudinal analysis of viral evolution from seroconversion
to up to 500 days p/s revealed the dynamic nature of the in vivo muta-
tional pathways in HIV-1C Gag, and their complexity at selected amino
acid residues. A high fraction of identiﬁed Gag substitutions, i.e., forward
substitutions, was transient orminor. In contrast, themajority of Gag re-
verse substitutions were found to be ﬁxed. A substantial inter-patient
heterogeneity was evident in the patterns of appearance, dominance,
and ﬁxation of identiﬁed amino acid substitutions in HIV-1C Gag.
A considerable fraction of Gag reverse substitutions, 73.7%, reached
dominance and/or ﬁxation during the ﬁrst year of HIV-1 subtype C infec-
tion, supporting the hypothesis that reverse substitutions in Gag are
Minor Gag substitions:
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0-100 101-200 201-300 301-400 401-500
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Fig. 3. Relationships between reverse and forward substitutions in HIV-1C Gag over time. The number of identiﬁed amino acid substitutions is shown in the left bottom corner of
each graph. Analyzed time intervals in days from estimated seroconversion, the number of subjects, and the number of analyzed sequences per time interval including total, RNA,
and DNA are shown at the bottom. A: Minor Gag substitutions (did not reach dominance or ﬁxation, and did not disappear over the follow up time). B: Transient Gag substitutions.
C: Dominant Gag substitutions (did not reach ﬁxation over the follow up time). D: Fixed substitutions.
123V. Novitsky et al. / Virology 421 (2011) 119–128driven by viral ﬁtness cost, e.g., ability of reverse substitutions to restore
viral ﬁtness. In contrast, only a small fraction of Gag forward substitu-
tions, 10.2%, reached dominance or ﬁxation. More than half of the
detected forward substitutions, 58.5%, were transient. Given a relatively
short period of detection of some transient substitutions even with fre-
quent sampling, this is likely a conservative estimate. We propose that
at least three mechanisms may account for a large fraction of transient
forward substitutions in HIV-1 subtype C Gag. First, transient substitu-
tions may represent mutational noise, although a relatively large overall
number of transient substitutions might have a negative impact bydiverting immune responses and exhausting the immune system. Sec-
ond, assuming random appearance, transient substitutions are generated
stochastically, they can dramatically reduce viral ﬁtness, and therefore
can be eliminated quickly from thepool of viral quasispecies. Third, hypo-
thetically, transient substitutionsmight induce potent immune responses
within a short period of time, and therefore become eliminated by im-
mune pressure. If the last assumption is true, then certain transient sub-
stitutions could represent an attractive target for HIV vaccine design due
to their potent immunogenicity. According to this scenario, a vaccine an-
tigenwith transient amino acid substitutionsmight rapidly induce a long
Reverse substitutions:
Transient substitutions
Minor substitutions
Forward substitutions:
0-100 101-200 201-300 301-400 401-500
TIME INTERVALS, days from estimated seroconversion
A
B
Dominant substitutions
Fixed substitutions
n=75 n=138 n=71 n=32 n=33
n=28 n=70 n=245 n=180 n=156
Fig. 4. Relationships between different types of reverse and forward Gag substitutions over time. The number of identiﬁed substitutions is shown in the left bottom corner of each
graph. Analyzed time intervals in days from estimated seroconversion are shown at the bottom. A: Reverse substitutions. B: Forward substitutions.
124 V. Novitsky et al. / Virology 421 (2011) 119–128lasting immune response of high magnitude that cannot be achieved in
natural infection due to fast elimination of such viral variant by immune
pressure. A high magnitude of the induced immune response might
cause cross-reactivity toward viral variants without transient substitu-
tion, and if so, should have a protective effect. Presence of both ﬁxed
and transient viral substitutions indicates that the overall immune0%
10%
20%
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Fig. 5. Proportion of individuals with detectable amino acid substitutions in Gag over
time. Individuals with detectable reverse substitutions are shown by dark bars. Individ-
uals with detectable forward substitutions are shown by light bars. Analyzed time in-
tervals in days from estimated seroconversion are shown at the bottom.responses to HIV-1 Gag epitopes are substantial, but also provides evi-
dence for a fast appearance of viral variants.
The reverse substitutions play an important role on the popula-
tion level (Matthews et al., 2008) through their ability to restore
the subtype consensus sequence. Upon virus transmission between
HLA-distinct hosts and apparent shift in the speciﬁcities of HLA re-
striction, at least some forward substitutions that were generated
in previous host revert to the subtype consensus. Thus, being ampli-
ﬁed on a population level, the reverse substitutions maintain the
subtype consensus sequence of virus in epidemic. Despite the in-
crease in overall viral diversity, the stability of HIV-1C Gag consensus
sequence in the epidemic over time is striking (Novitsky et al.,
2010a,b). A relatively low proportion of amino acid substitutions
within known CTL epitopes might indicate that only fraction of CTL
epitopes have been mapped in HIV-1C infection, and warrants fur-
ther studies.
Utilizing the HIV-1 subtype consensus sequence might be biased
to the extent of representative sampling in the epidemic, which is
one of the study limitations. However our previous analyses demon-
strated an extreme similarity between the HIV-1C consensus se-
quences originating from different geographic areas or collected at
different time points (Novitsky et al., 2002, 2010b). Another study
limitation is that some early reverse and forward substitutions
could be missed due to the time of sampling. Samples with the ﬁrst
available sequence in Fiebig stage V might be particularly affected.
Therefore, the current study had little to no power to address the ear-
liest amino acid substitutions in Gag.
In summary, this study addressed the breadth and relationships of
in vivo Gag substitutions in primary HIV-1 subtype C infection using a
direct mapping of Gag amino acid substitutions along the time line of
HIV-1 infection. The study contributes to better understanding of
early events in HIV infection and might assist in facilitating the devel-
opment of preventive strategies.
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Study subjects
Longitudinal sets of gag sequences were analyzed in subjects en-
rolled in a primary HIV-1 subtype C infection cohort in Botswana
(Novitsky et al., 2008, 2009c,d) from April 2004 to April 2008. A
total of 42 enrolled subjects included 8 detected with acute HIV-1 in-
fection (Fiebig stage II) and 34 detected with “recent” infection (Fie-
big stage IV or V). Details on estimating time of seroconversion are
provided elsewhere (Novitsky et al., 2009b). A “zero” time corre-
sponded to seroconversion, as a more accurate and measurable
time point than estimation the time of HIV infection (Novitsky et
al., 2010c). The time of HIV infection can be estimated by adding
14 to 21 days. The median (IQR) time elapsed between estimated
time of seroconversion and ﬁrst available sequence was 44.0 (10.8
to 54.0) days. There were 9 male (2 acute) and 33 female (6 acute)participants. The median age at enrollment was 27 years (IQR 25–
32, range 20–56). All subjects were Botswana nationals, and all in-
fections were HIV-1 subtype C (Novitsky et al., 2009a,d). As de-
scribed previously (Novitsky et al., 2008, 2009a,d), viral load and
CD4+ T cell counts were assessed during follow-up. Blood samples
were analyzed at median (IRQ) of 5 (4–6) time points per subject.
The follow up period was 415 (321–447) days post-seroconversion
(p/s). Ten of 42 (24%) subjects initiated ART within the observed pe-
riod of time due to a drop in CD4+ T cells (time of ART initiation, if
any, is shown in Table S1). The study was approved by Institutional
Review Boards in Botswana and the US. Written informed consent
was obtained from each participant.
Single-genome ampliﬁcation and sequencing
Previous evolutionary studies demonstrated that the HIV-1 gag
and env sequences derived from PBMC are comparable to viruses
126 V. Novitsky et al. / Virology 421 (2011) 119–128circulating in plasma (Geels et al., 2003; Shankarappa et al., 1999).
The similarities between viral sequences originating from alternative
templates, viral RNA and proviral DNA, are particularly evident at the
early phase of HIV infection (Novitsky V., unpublished data). In this
study both viral RNA from plasma and cell-associated proviral DNA
were used as templates for ampliﬁcation of viral sequences. Single ge-
nome ampliﬁcation and direct sequencing was performed as de-
scribed previously (Novitsky et al., 2009c, 2010c). Sequence contigs
were assembled by SeqScape v.2.6. Multiple sequence alignment
was performed by HIV-align at the Los Alamos HIV Database site
(http://www.hiv.lanl.gov/) using the hidden Markov model and the
codon-alignment option followed by minor manual adjustments in
BioEdit (Hall, 1999). The obtained sequences were tested by HYPER-
MUT v.2.0 (Rose and Korber, 2000) and hypermutated sequences
were excluded from analysis. A total of 2595 gag sequences included
827 sequences originating from the viral RNA template, and 1768 se-
quences obtained from the proviral DNA template. The median (IQR)
of analyzed gag sequences was 11.7 (8.8–13.9) per time point, and
61.5 (43.3–76.0) per subject. The accession numbers of the analyzed
gag sequences are GQ275380–GQ277569, GQ375107–GQ375128,
and GQ870874–GQ871183.
Amino acid frequencies in the pool of viral quasispecies
Only non-synonymous substitutions were analyzed in this study.
The frequencies of translated amino acid sequences in Gag were ana-
lyzed using MargFreq (Ray, 2008) per time point per subject. The fre-
quency of each amino acid was expressed as a fraction of 1 in the pool
of viral quasispecies at a given time point. Frequency changes in the
pool of viral quasispecies at each amino acid position over time
were tracked according the following criteria. If any change in the
proportion of amino acid(s) in the pool of viral quasispecies was ob-
served over time, the amino acid with increased frequency was the
subject of frequency assessment. Sites with a single amino acid pre-
sent in the pool of the earliest available quasispecies were examined
for appearance of any alternative amino acid over the time of follow
up, and the new amino acid was subject for evaluation. Examples of
this approach were presented elsewhere (e.g., Fig. 2 in Novitsky et
al. (2010c)). If two amino acids were present in the pool of the earli-
est quasispecies, the amino acid that showed an increase in frequency
over time was a subject for analysis. Although multiple amino acids
can be present in the pool of viral quasispecies, we observed no
cases with more than two amino acids at the earliest time points in
this study. Therefore, no sites with multiple increasing amino acids
were detected.
Types of amino acid substitutions
By analogy with drug-resistance mutations, we deﬁne a mutation-
al pathway as a series of sequential changes in the pool of viral qua-
sispecies at a single or at multiple amino acid positions over time.
Parameters quantiﬁed in this study include sequential frequency of
observed amino acids over time in relation to the estimated time of
seroconversion. At each position in amino acid alignment, the ob-
served amino acid substitutions were classiﬁed based on their rela-
tion to subtype C consensus sequence, and fraction in the pool of
viral quasispecies.
In analysis of relationships between the observed in vivo Gag sub-
stitutions and the subtype consensus, an amino acid substitution from
the consensus amino acid to the non-consensus was treated as a for-
ward substitution (a potential escape mutation that requires experi-
mental conﬁrmation of immune escape). In this study, an amino acid
substitution from a non-consensus amino acid to the consensus-
matched amino acid was considered a reverse substitution, or reversion
(note: the alternative interpretation of reverse substitution is related to
the transmitted virus, and was not used in this study). Viralsubstitutions that did not involve the most common HIV-1 subtype C
amino acid were treated as non-subtype-consensus-related polymor-
phisms. Testing of immune responses was out of the scope of the
study, resulting in a lack of evidence that observed viral substitutions
are directly linked to immune responses.
Based on the frequency in the pool of viral quasispecies, we cate-
gorized amino acid substitutions as minor, dominant, ﬁxed, and tran-
sient. A substitution was considered minor if its fraction was less
than or equal to 50% in the pool of viral quasispecies during follow-
up. A substitution was treated as dominant if its fraction reached
more than 50% in the pool of viral quasispecies but did not reach com-
plete substitution of the original amino acid. A substitution was ﬁxed
if it reached 100% in the pool of viral quasispecies during the follow-
up period. A substitution was considered transient if its frequency
subsequently decreased below 1.0 for ﬁxed substitutions, or below
0.5 for dominant substitutions, or if minor substitution disappeared
over the observation period. Once amino acid substitutions in Gag
reached the state of dominance or ﬁxation, they rarely disappeared
but rather shared their frequency in the pool of viral quasispecies
with alternative amino acid(s) by balancing and frequency ﬂuctua-
tion over time. Thus, in this study transient substitutions are predom-
inantly those that were minor and disappeared from the pool of viral
quasispecies.
MHC class I HLA typing
High resolution HLA typing was performed for all study subjects as
described previously (Novitsky et al., 2009c). Brieﬂy, the AlleleSEQR
HLA Sequencing-Based Typing kit (Celera, Alameda, CA) was used
according to the manufacturer's instruction. Contig assembling and as-
signment of HLA alleles was implemented by Assign SBT ver. 3.5.1.42
(Conexio Genomics, Applecross, Australia). All ambiguous positions
were resolved by re-sequencing. Polymorphisms outside the targeted
exons that could not resolve heterozygote combinations were inter-
preted as two-digit HLA typing results.
CTL epitopes analysis
The Los Alamos National Laboratory HIV immunology database
(http://www.hiv.lanl.gov/content/immunology) was screened for
known human CTL epitopes identiﬁed in the context of HIV-1 subtype
C infection and the MHC class I HLA alleles restriction. For each sub-
ject, the location of the observed amino acid substitutions in Gag
was matched with the retrieved epitopes restricted by the corre-
sponding class I HLA alleles. The number of matched amino acid sub-
stitutions within known CTL epitopes in the context of their class I
HLA restriction was used for analysis the proportion of Gag substitu-
tions within CTL epitopes.
Statistical analysis
Data are summarizedwithmedians (IQR range for 25% and75%). Fre-
quencies of amino acid substitutions by type over time are presented.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.09.020.
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